08:35 AM EST, 12/16/2024 (MT Newswires) -- Mind Medicine (MNMD) said Monday that a first patient has been dosed in its phase 3 Voyage study that is evaluating MM120 ODT for the treatment of generalized anxiety disorder.

The company said the trial is the first of two phase 3 studies evaluating the efficacy and safety of MM120 ODT versus placebo. Mind Medicine said the second study, called Panorama, will be conducted in the US and Europe and is expected to be initiated in H1 2025.